Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
iTeos Therapeutics (ITOS)
NASDAQ:ITOS
Holding ITOS?
Track your performance easily
ITOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.41 - $18.75
Previous Close$9.22
Volume792.21K
Average Volume (3M)659.24K
Market Cap
$327.60M
Enterprise Value-$238.14M
Total Cash (Recent Filing)$571.26M
Total Debt (Recent Filing)$5.52M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 06, 2024EPS Estimate
-$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding36,521,845
10 Day Avg. Volume611,134
30 Day Avg. Volume659,241
Standard Deviation0.20
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.51
Price to Sales (P/S)9.36
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.80
Enterprise Value/Gross Profit-18.91
Enterprise Value/Ebitda2.31
Forecast
1Y Price Target
$34.25Price Target Upside264.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
iTeos Therapeutics News
PremiumCompany Announcements
Officina Stellare Secures €1.4 Million Satellite Contract
PremiumCompany Announcements
iTeos Therapeutics Reports Positive Phase 2 Cancer Trial Results
Bulls Say, Bears Say
Bulls Say
Drug DifferentiationBelrestotug stands out as the only anti-TIGIT in development showing monotherapy activity in Phase 1, indicating its differentiated and potentially more effective approach.
EfficacyThe combination therapy of belrestotug and dostarlimab in non-small cell lung cancer has demonstrated a confirmed 61% overall response rate, significantly higher than the 28% seen with dostarlimab alone.
Financial OutlookThe current valuation of the stock is considered attractive, with multiple promising projects underway and sufficient cash reserves to support pivotal studies, offering potential for a 5-20% upside with limited downside risk.
Bears Say
CompetitionEven though belrestotug and tiragolumab could have first-to-market advantage in the anti-TIGIT space if approved, they could eventually face strong competition from Fc-reduced/silenced anti-TIGIT therapies.
Discontinuation RatesDiscontinuation rates came in a bit high at the 1000mg dose.
Safety ProfileThe safety data of the GALAXIES Lung-201 study confirms that Fc-competent anti-TIGIT antibodies are associated with an increased risk of immune-related adverse events.
---
Ownership Overview
24.39% Insiders
12.80% Mutual Funds
0.16% Other Institutional Investors
50.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITOS FAQ
What was iTeos Therapeutics’s price range in the past 12 months?
iTeos Therapeutics lowest stock price was $8.41 and its highest was $18.75 in the past 12 months.
What is iTeos Therapeutics’s market cap?
Currently, no data Available
When is iTeos Therapeutics’s upcoming earnings report date?
iTeos Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is yesterday.
How were iTeos Therapeutics’s earnings last quarter?
iTeos Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$1.038 by $0.858.
Is iTeos Therapeutics overvalued?
According to Wall Street analysts iTeos Therapeutics’s price is currently Undervalued.
Does iTeos Therapeutics pay dividends?
iTeos Therapeutics does not currently pay dividends.
What is iTeos Therapeutics’s EPS estimate?
iTeos Therapeutics’s EPS estimate is -$1.17.
How many shares outstanding does iTeos Therapeutics have?
iTeos Therapeutics has 36,521,847 shares outstanding.
What happened to iTeos Therapeutics’s price movement after its last earnings report?
iTeos Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$1.038. Following the earnings report the stock price went down -1.577%.
Which hedge fund is a major shareholder of iTeos Therapeutics?
Among the largest hedge funds holding iTeos Therapeutics’s share is RA Capital Management. It holds iTeos Therapeutics’s shares valued at 52M.
---
iTeos Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.25 (264.17% Upside)
$34.25 (264.17% Upside)
Blogger Sentiment
Bullish
ITOS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 864.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.83%
12-Months-Change
Fundamentals
Return on Equity
-16.80%
Trailing 12-Months
Asset Growth
6.83%
Trailing 12-Months
Company Description
iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
---
ITOS Stock 12 Month Forecast
Average Price Target
$34.25
▲(264.17% Upside)
Technical Analysis
Best Analysts Covering ITOS
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-14.59%
assigned a buy rating 2 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -14.59% per trade.
---